LGVN News

Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

Longeveron Announces Closing of Private Placement of up to $30 Million

Longeveron Announces Private Placement of up to $30 Million

Form 8-K

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)